Cell Therapy Manufacturing Facility
Courtesy of Johnson & Johnson
Johnson & Johnson is investing over $1 billion to create a next-generation cell therapy manufacturing facility in Lower Gwynedd Township, Pa. The state-of-the-art hub is part of a $55 billion commitment to expand the company’s infrastructure and capacity in the United States by early 2029, and supports plans to produce the vast majority of J&J’s innovative medicines domestically to meet the needs of U.S. patients. Utilizing leading-edge cell therapy technologies, the center will advance transformational treatments for cancer, immune-mediated diseases, and neurological conditions. The complex will be operated by subsidiary firm Janssen Biotech.
The development will generate more than 4,000 construction jobs and 500 biomanufacturing positions, while further strengthening the company's annual $10 billion economic impact in Pennsylvania. With 10 facilities encompassing more than 2 million sf of space dedicated to manufacturing, research, distribution, and office operations, Johnson & Johnson maintains one of the most significant statewide footprints in the healthcare industry. The Commonwealth is contributing to the project through a $41.5 million economic incentive package, as well as up to $2.5 million through the Redevelopment Assistance Capital Program for a workforce training initiative to establish a talent pipeline in collaboration with local educational institutions.
Located in Montgomery County, the 154-acre property was purchased in 2022 for $31.5 million and accommodates an existing 157,000-sf structure. The company intends to fully participate in TrumpRx.gov, a direct-to-patient platform that will enable millions of Americans to purchase medicines at reduced rates. Opening in 2031, the plant will be delivered through the PA Permit Fast Track Program, which streamlines and accelerates timelines by coordinating permitting activities across government agencies and with private partners.
